Since March 2018 the Midlands and Wales ATTC (MW-ATTC) has been working to make advanced therapies routine and support adoption within NHS hospitals as more conventional treatments. The news of this programme has spread and the consortium were approached by the University Hospitals of Leicester NHS Trust about the programme and they have been accepted into the consortium.
University Hospitals of Leicester NHS Trust covers a population of approximately 1 million residents of Leicestershire and Rutland and brings further experience of running dendritic cell ATMP trials into the MW-ATTC consortium.
Innovate UK has approved the inclusion of University Hospitals of Leicester NHS Trust into the MW-ATTC. The staff from Leicester hospitals will not only contribute to the programme, they will also benefit from the knowledge already gained from across MW-ATTC and the wider ATTC network. The ATTC Network Programme is a world-first, UK system of Advanced Therapy Treatment Centres operating within the NHS framework to address the unique and complex challenges of bringing pioneering advanced therapy medicinal products (ATMPs) to patients.
